Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹150 | ₹100 |
Expense Ratio | 1.05 | 1.36 |
NAV | ₹17.84 | ₹200.79 |
Fund Started | 04 Oct 2022 | 07 May 2007 |
Fund Size | ₹948.83 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 30 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -2.88% | 7.61% |
3 Year | 20.41% | 25.90% |
5 Year | - | 29.74% |
1 Year
3 Year
5 Year
Equity | 100.01% | 93.60% |
Cash | -0.01% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.91% |
Max Healthcare Institute Ltd. | 4.79% |
Suzlon Energy Ltd. | 4.00% |
BSE Ltd. | 3.89% |
Solar Industries India Ltd. | 3.65% |
Coforge Ltd. | 3.54% |
Fortis Healthcare Ltd. | 3.30% |
One97 Communications Ltd. | 3.27% |
SRF Ltd. | 3.23% |
HDFC Asset Management Company Ltd. | 3.14% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Sailesh Jain | Chirag Setalvad |
Start Date | 05 May 2025 | 28 Jun 2014 |
Name
Start Date
Description | The scheme is seeks to provide returns, before expenses, that commensurate with the performance of NIFTY Midcap 150 Momentum 50 Index (TRI), subject to tracking error. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 04 Oct 2022 | 07 May 2007 |
Description
Launch Date